An official website of the United States government
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
Trial Status: active
The goal of this clinical trial is to evaluate the safety, tolerability, and recommended
Phase 2 Dose (RP2D) of KLN-1010 in patients with relapsed or refractory multiple myeloma.
Inclusion Criteria
Participants must have relapsed and refractory multiple myeloma (RRMM) with measurable disease
Participants must have received at least 3 prior lines of therapy including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and CD38-directed monoclonal antibody
Participants must have an Eastern Cooperative Group (ECOG) performance status of 0-1
Participants must have acceptable laboratory values as defined by the protocol
Exclusion Criteria
Participants must not have known central nervous system (CNS) involvement with myeloma
Participants cannot have plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, and skin changes) syndrome, or primary light chain amyloidosis
Participants cannot have ongoing acute systemic infection requiring antimicrobial therapy
Participants cannot require systemic steroids for any condition
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT07075185.
